New approaches leverage IVT mRNA in cancer

Following the success of IVT mRNA COVID-19 vaccines, therapeutic applications based on this new efficient and accessible modality are rapidly evolving. As evidenced by this year’s ADLM (formerly AACC) meeting, IVT mRNA is providing innovative solutions to improve cancer immunotherapies. In this application note, Genscript highlights clinical and preclinical studies expanding the reach of mRNA medicines in cancer.